|
|
Type of Company:
Type:
|
Company
|
Ownership: |
Publicly Traded (AUPH, NASDAQ) |
Company Size: |
20-49 Employees In BC (20-49 Total)
20-49 In BC (20-49 Total)
|
Year Founded: |
2013 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Vancouver Island
Vancouver Island
|
Tags: |
Aurinia, biopharmaceutical, lupus, debilitating diseases
|
Profile Views: |
1,156 Company Profile Views |
|
|
|
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis.
The company is headquartered in Victoria, British Columbia, its U.S. commercial hub in Rockville, MD, and focuses its development efforts globally. For further information, see our website at www.auriniapharma.com |
|
|
Date |
Type |
Amount |
Investors |
Dec 10, 2019 |
Unattributed |
$166.7 Million USD |
underwritten public offering of 11,115,165 common shares |
Jul 27, 2020 |
Unattributed |
$200 Million USD |
Public offering of 13,333,334 common shares. The shares were sold at a public offering price of US$15.00 per share |
Date |
Type |
Amount |
Investors |
Dec 10, 2019 |
Unattributed |
$166.7M USD |
underwritten public offering of 11,115,165 common shares |
Jul 27, 2020 |
Unattributed |
$200M USD |
Public offering of 13,333,334 common shares. The shares were sold at a public offering price of US$15.00 per share |
|
|
|
Want More Aurinia Pharmaceuticals Inc. News? 1 2 3 4 5
|
Next »
|
|
|
|
|
|
|
Mar 3, 2021
|
Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights (Reports Cash Liquidity of US $423M)
|
|
Jan 26, 2021
|
Victoria-based Aurinia Announces U.S. FDA Approval for its LUPKYNIS Therapy for Adult Patients with Active Lupus Nephritis - Stock Soars 26%
|
|
Dec 31, 2020
|
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
|
|
Dec 29, 2020
|
Aurinia Receives Upfront Payment of U.S. $50 Million for Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co.
|
|
Nov 10, 2020
|
Victoria, BC-based Aurinia Pharmaceuticals Announces Outcome of AUDREY Clinical Trial in Dry Eye Syndrome
|
|
Sep 30, 2020
|
Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome
|
|
Aug 19, 2020
|
Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights
|
|
Aug 4, 2020
|
Victoria-based BioPharm Company Aurinia Announces U.S. FDA Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin
|
|
Jul 29, 2020
|
Victoria-based Aurinia Hauls in Another US$200 Million Financing (Public Offering of Common Shares)
|
|
Jun 23, 2020
|
Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Solution for the Treatment of Dry Eye Syndrome
|
|
|
1 - 10 of 45 results
|
|
 |
|
|
|
Share This Company Profile |
|
|
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
